RxDoctor Payments Data

Julie Bortolotti, MD

Family Medicine · Houston, TXNPI 1457360661

Payments from drug & device makers

$3,318in general payments, 2019–2025

Across 173 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$767
  • Pfizer$453
  • AstraZeneca$315
  • Novo Nordisk$236
  • GSK$232
  • AbbVie$186
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,26598%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,318 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,860
Medicare patients
187
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$43,162
TrulicityDulaglutide23$41,935
JardianceEmpagliflozin20$30,147
JanuviaSitagliptin Phosphate22$27,242
EliquisApixaban18$23,240
FarxigaDapagliflozin Propanediol11$15,643
TradjentaLinagliptin14$15,610
SynthroidLevothyroxine Sodium85$7,777
Levothyroxine Sodium443$4,679
Atorvastatin Calcium394$3,840
BreynaBudesonide/Formoterol Fumarate11$3,036
Losartan Potassium288$2,916
Duloxetine Hcl99$2,554
SymbicortBudesonide/Formoterol Fumarate11$2,524
Metoprolol Succinate158$2,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$236$43,16238 claims
Lilly USA, LLCTrulicity$767$41,93523 claims
MerckJanuvia$93$27,24222 claims
PfizerEliquis$453$23,24018 claims
AstraZenecaFarxiga, Symbicort$315$18,16722 claims
AbbVieSynthroid$186$7,77785 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →